Goldman Sachs & Co. LLC and J.P. Morgan are acting as lead book-running managers for the offering. Allen & Company LLC is acting as book-running manager for the offering. Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal, the San Francisco Bay Area, and London. Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ:RXRX), a leading ...

The most recent trading session ended with Recursion Pharmaceuticals (RXRX) standing at $9.38, reflecting a +0.43% shift from the previouse trading day's closing. The stock's performance was ahead of the S&P 500's daily gain of 0.09%. Elsewhere, the Dow saw a downswing of 0.1%, while the tech-heavy Nasdaq appreciated by 0.16%. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$1.60 per share and revenue of $45.99 million. These totals would mark changes of - ...

"Since our last Download Day, which was approximately 18 months ago, we have seen various industries increasingly embrace AI/ML solutions. This adoption has also played out in the drug discovery space," said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion. "Over the past decade, we have created a strong leadership position by building the technological and operational capabilities of our platform in order to expand and advance our internal pipeline as well as deliver for our external partners through t ...

Recursion delivered multiple data packages to Bayer and initiated the first joint oncology project, which is now expected to advance rapidly towards Lead Series nomination Bayer to become first external beta-user of LOWE (LLM-Orchestrated Workflow Engine) for drug discovery and development SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will give updated pipeline guidance to investors, anal ...

To address this issue, companies like Recursion are trying to identify failures early on and accelerate pre-clinical development of high potential drug candidates. While there is likely significant value just in improving the productivity of pre-clinical research, late-stage clinical failures are the primary driver of costs in today's pharmaceutical R&D model, making improving clinical success rates critical to improving the return on R&D spend. Recursion believes that the development and convergence of a r ...

Investing in growth stocks can lead to significant returns for investors in the long run. But oftentimes, the best returns come from smaller stocks, which have modest market values. These stocks can be risky options, but due to their low valuations, they tend to have the most room to rise higher if their businesses prove to be the real deal. Recursion hopes that it can help develop its own pipeline with cutting-edge technology while also helping other companies. While there isn't anything significant to sho ...

SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Jefferies Healthcare Conference - June 5-6, 2024 45th Annual Goldman Sachs Healthcare Conference - June 10-13, 2024 Morgan Stanley 3rd Annual Life Sciences AI Summit - June 26-27, 2024 About Recursion Recursion is a clinical stage TechBio company leading the space by decod ...

SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature Genetics scientific findings that highlights a potential limitation of CRISPR-Cas9 in gene editing - a key component in understanding disease mechanisms, and developing new therapeutic approaches. Investor Contact This proximity bias, discoverable through Recursion's proprietary biological dataset, could have many down ...

SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature Genetics scientific findings that highlights a potential limitation of CRISPR-Cas9 in gene editing - a key component in understanding disease mechanisms, and developing new therapeutic approaches. "Over several years, Recursion has built both unique scale and experience of working with CRISPR-Cas9. By combining the mas ...

Company Leadership Update - Robert Hershberg, MD, PhD, has been appointed as the new Chair of the Board of Recursion, effective at the end of the current term, replacing Martin Chavez who is stepping down after more than four years of leadership [1] - Dr Hershberg brings extensive experience in drug discovery and commercialization, having served on Recursion's Board since May 2020 and holding leadership roles at HilleVax, Celgene, and VentiRx Pharmaceuticals [2] - Chris Gibson, CEO and Co-founder of Recursion, expressed excitement about Dr Hershberg's appointment and gratitude for Martin Chavez's contributions to the company's growth [3] Company Overview - Recursion is a clinical-stage TechBio company that decodes biology to industrialize drug discovery, leveraging its proprietary Recursion OS platform and one of the world's largest biological and chemical datasets [4] - The company conducts millions of wet lab experiments weekly and operates one of the most powerful supercomputers in the world, combining technology, biology, and chemistry to advance medicine [4] - Recursion is headquartered in Salt Lake City and has offices in Toronto, Montréal, and the San Francisco Bay Area [5] Industry Impact - Recursion is positioned as a leader in the TechBio space, which is expected to revolutionize the biopharma industry through the intersection of scientific rigor and technology [3] - The company's approach to drug discovery, unconstrained by human bias and enabled by machine learning, represents the future of the industry [2]